Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Declines By 61.9%

Posted by Geri Gentry on Aug 14th, 2026

GeoVax Labs Inc. (NASDAQ:GOVX – Get Free Report) was the target of a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 57,276 shares, a drop of 61.9% from the July 15th total of 150,485 shares. Based on an average daily trading volume, of 220,342 shares, the short-interest ratio is presently 0.3 days. Currently, 1.7% of the company’s shares are sold short.

GeoVax Labs Trading Down 1.1%

GOVX opened at $0.72 on Friday. The company has a market cap of $2.49 million, a price-to-earnings ratio of -0.06 and a beta of 3.73. The company’s fifty day moving average price is $1.05 and its two-hundred day moving average price is $1.54. GeoVax Labs has a 1-year low of $0.64 and a 1-year high of $20.00.

GeoVax Labs (NASDAQ:GOVX – Get Free Report) last issued its quarterly earnings data on Monday, July 27th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.16) by $1.19. As a group, equities analysts forecast that GeoVax Labs will post -4.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds have recently made changes to their positions in the stock. Ieq Capital LLC purchased a new position in GeoVax Labs during the second quarter valued at approximately $1,352,000. NFJ Investment Group LLC bought a new position in GeoVax Labs in the 2nd quarter worth about $1,419,000. Rice Hall James & Associates LLC purchased a new stake in shares of GeoVax Labs in the 2nd quarter valued at about $1,888,000. Jane Street Group LLC bought a new stake in shares of GeoVax Labs during the 1st quarter valued at about $27,000. Finally, HRT Financial LP purchased a new position in shares of GeoVax Labs during the fourth quarter worth about $31,000. 6.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on GOVX. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a research note on Sunday, June 21st. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of GeoVax Labs in a research report on Thursday, April 16th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $150.00.

Get Our Latest Stock Report on GeoVax Labs

GeoVax Labs Company Profile

(Get Free Report)

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.